A detailed history of Manufacturers Life Insurance Company, The transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 23,774 shares of FULC stock, worth $105,081. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,774
Previous 24,480 2.88%
Holding current value
$105,081
Previous $151,000 44.37%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.18 - $9.74 $2,245 - $6,876
-706 Reduced 2.88%
23,774 $84,000
Q2 2024

Aug 14, 2024

BUY
$5.98 - $9.31 $146,390 - $227,908
24,480 New
24,480 $151,000
Q2 2023

Aug 11, 2023

SELL
$2.26 - $3.8 $38,465 - $64,676
-17,020 Closed
0 $0
Q4 2022

Aug 11, 2023

BUY
$5.01 - $8.35 $10,065 - $16,775
2,009 Added 13.38%
17,020 $123,000
Q4 2022

Feb 13, 2023

BUY
$5.01 - $8.35 $10,065 - $16,775
2,009 Added 13.38%
17,020 $123,000
Q3 2022

Aug 11, 2023

BUY
$4.92 - $9.1 $201 - $373
41 Added 0.27%
15,011 $119,000
Q3 2022

Nov 03, 2022

BUY
$4.92 - $9.1 $201 - $373
41 Added 0.27%
15,011 $121,000
Q2 2022

Aug 11, 2023

BUY
$4.2 - $24.0 $14,271 - $81,552
3,398 Added 29.36%
14,970 $73,000
Q2 2022

Aug 15, 2022

BUY
$4.2 - $24.0 $14,271 - $81,552
3,398 Added 29.36%
14,970 $73,000
Q1 2022

Aug 11, 2023

SELL
$9.96 - $23.65 $54,262 - $128,845
-5,448 Reduced 32.01%
11,572 $273,000
Q1 2022

May 20, 2022

SELL
$9.96 - $23.65 $27,579 - $65,486
-2,769 Reduced 19.31%
11,572 $274,000
Q4 2021

Feb 16, 2022

BUY
$14.0 - $28.44 $4,676 - $9,498
334 Added 2.38%
14,341 $254,000
Q3 2021

Nov 12, 2021

BUY
$7.28 - $30.97 $101,970 - $433,796
14,007 New
14,007 $395,000
Q2 2021

Aug 12, 2021

SELL
$8.09 - $12.0 $92,711 - $137,520
-11,460 Closed
0 $0
Q1 2021

May 03, 2021

BUY
$10.94 - $15.32 $125,372 - $175,567
11,460 New
11,460 $135,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $230M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.